Ph2/3 study to evaluate the safety of telisotuzumab in combo with NSCL
Phase II/III Clinical Trial
A Phase 2/3 Randomized Study to Evaluate the Safety Efficacy and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer